Earlier this year, Walgreens made a significant move by partnering with Sycamore Partners, a private equity firm, culminating in a substantial deal valued at billion that was finalized in late August. This strategic alliance has raised eyebrows within the industry, as numerous experts express concerns about the implications of such a sale amid the numerous challenges facing the retail health sector. The decision to engage with private equity is seen by some as a necessary measure, yet others worry about the long-term effects on Walgreens’ operational stability and service delivery.
Many industry analysts are apprehensive about Walgreens’ future trajectory post-sale. Historically, private equity firms like Sycamore Partners typically aim to exit their investments within a five to seven-year timeframe. This creates uncertainty about the sustainability of Walgreens’ operations and its ability to navigate long-term healthcare challenges.
“The healthcare sector fundamentally revolves around long-term patient care and maintaining health over extended periods. However, the business model of private equity is predominantly focused on short-term gains,” stated Matt Parr, communications director for the Private Equity Stakeholder Project, a nonprofit organization that monitors private equity activities. This model often involves maximizing profits quickly, which may not align with the essential values of healthcare.
As part of the restructuring under Sycamore, Walgreens will reorganize into five distinct entities: Walgreens (focusing on pharmacy services), The Boots Group (dedicated to health and beauty retail), Shields Health Solutions (offering specialty pharmacy solutions), CareCentrix (providing home health services), and VillageMD (centered on primary care). This division aims to streamline operations but raises questions about the impact on service delivery across communities.
Both Sycamore Partners and Walgreens have chosen not to provide any comments regarding the deal and its subsequent implications.
What Challenges Might Walgreens Face in the Future?
There are several factors that contribute to Parr’s concerns regarding the sale to Sycamore Partners. One significant issue is that over 70% of the deal is financed through debt, indicating that Sycamore Partners does not have a substantial financial stake in the operation. This raises alarms about the long-term viability of Walgreens, especially given its previous financial struggles.
“Walgreens has already faced numerous financial difficulties, and adding substantial debt could exacerbate these issues,” Parr explained. He noted that in the first quarter of the current year, approximately 70% of major bankruptcies in the country were linked to private equity-backed firms, which adds to the growing concern about Walgreens’ stability.
Furthermore, Walgreens serves as a vital pharmacy provider in many communities. Any financial setbacks could directly affect consumers who rely on its services for essential medications. The ramifications of financial instability could lead to reduced access to healthcare for those most in need.
However, the debt financing and existing financial challenges are not the only reasons for Parr’s unease. The replacement of Walgreens CEO Tim Wentworth with Mike Motz, the former CEO of Staples, another company under Sycamore’s umbrella, is also a point of concern. “Under Motz’s leadership, Staples closed a significant number of stores and eliminated tens of thousands of jobs,” he remarked. “If Sycamore applies similar strategies to Walgreens, we could see substantial store closures and layoffs, contributing to pharmacy deserts in neighborhoods already lacking access to reliable healthcare services.”
Sycamore Partners has a track record of overseeing substantial bankruptcies, including notable names like Belk, Nine West, and Aeropostale, which further fuels skepticism about the future of Walgreens.
Regarding the decision to break Walgreens into five separate companies, Parr speculates that this strategy may help Sycamore identify the most profitable segments, likely resulting in the closure of less profitable retail locations and workforce reductions in underperforming areas.
Are There Positive Perspectives on the Walgreens-Sycamore Deal?
Conversely, some experts view the disaggregation of Walgreens as a strategic move. Michael Greeley, cofounder and general partner at Flare Capital Partners, believes that separating the company into distinct entities was a wise decision. He notes that the retail sector in healthcare has faced significant pressures, and Walgreens’ retail operations were negatively impacting its higher-performing divisions like Shields and CareCentrix.
“Disaggregating these diverse assets has been a beneficial step,” Greeley asserted. Other healthcare professionals echo this sentiment, emphasizing that Walgreens has struggled to integrate its various assets into a cohesive experience for customers, which is likely why Sycamore has opted for this restructuring approach.
“The five new businesses will each have unique margin profiles, cost structures, and growth opportunities,” said Warren Templeton, managing director of Health2047, the venture studio for the American Medical Association. He compared Walgreens to CVS, which successfully leveraged its acquisition of Caremark to reduce drug costs and enhance customer acquisition through its merger with Aetna.
However, the reality remains that the restructuring will likely lead to store closures, which could adversely affect underserved communities. “Stores that are not profitable or lack the potential to generate free cash flow will be at risk of closure. The concern is whether they will close locations in markets that already face healthcare deprivation,” Greeley stated.
It is crucial to recognize that most of Sycamore’s past experiences have been in the retail sector, not healthcare. “This is not merely a typical retail acquisition; it presents a far greater challenge for Sycamore to manage,” Parr noted. “If Walgreens follows a similar path to smaller retail companies that have gone bankrupt under Sycamore’s management, the fallout could be significantly more severe than what was seen with Nine West.”
For ongoing updates on litigation, regulatory changes, deals, and trends in financial services, consider signing up for Finance Docket, a collaboration between Breaking Media publications Above the Law and Dealbreaker.
